

# Psoriasis - Pipeline Insight, 2021

<https://marketpublishers.com/r/PAC646203B9AEN.html>

Date: May 2021

Pages: 200

Price: US\$ 3,000.00 (Single User License)

ID: PAC646203B9AEN

## Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Psoriasis - Pipeline Insight, 2021," report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Psoriasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Psoriasis Understanding

#### Psoriasis: Overview

Psoriasis is a chronic inflammatory skin disorder that is accompanied with various clinical manifestations and is caused due to the involvement of genetic, environmental, and immunological factors (Rendon & Sch?kel, 2019). It is a non-contagious dermatosis disease affecting almost 2% of the world population. It can be observed in the form of recurring red and scaly skin plaques that can be prominently differentiated from the normal adjacent skin. The physical and psychological impact of psoriasis can be well-compared with those of diabetes, depression, heart disease and cancer. The percentage of body affected by psoriasis can vary on an individual basis. It is possible to observe mild (10%) psoriasis in different people, however the most commonly witnessed psoriasis is chronic plaque psoriasis or psoriasis vulgaris. It is a chronic

inflammatory skin disorder in which the dendritic cells, T lymphocytes, macrophages, neutrophils, and keratinocytes lead to skin lesions.

'Psoriasis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Psoriasis pipeline landscape is provided which includes the disease overview and Psoriasis treatment guidelines. The assessment part of the report embraces, in depth Psoriasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Psoriasis R&D. The therapies under development are focused on novel approaches to treat/improve Psoriasis.

## Psoriasis Emerging Drugs Chapters

This segment of the Psoriasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Psoriasis Emerging Drugs

### Bimekizumab: UCB

Bimekizumab (formerly UCB4940) is a novel humanized monoclonal antibody of the immunoglobulin G1 isotype, rationally designed to be able to bind at a similar site on both proinflammatory cytokine interleukin (IL)-17A and IL-17F, conveying dual inhibition of both isoforms. It is currently in preregistration stage for the treatment of Plaque psoriasis.

### ABP 654: Amgen

ABP 654 (ustekinumab) is a biosimilar candidate to reference product STELARA. It is a monoclonal antibody that inhibits IL-12 and IL-23. Amgen is evaluating ABP 654 in Phase III clinical studies for the treatment of Inflammation (Plaque psoriasis).

### MP1032: MetrioPharm

MP1032 belongs to a new class of anti-inflammatory drugs that act as potent ROS scavengers. A unique feature of this compound class is that the scavenging activity is dynamically regulated by an intracellular feedback loop. Scavenging activity increases with increased inflammatory activation of innate immune cells and ceases at physiological, non-inflammatory activation states. It is currently in phase 2 of development stage for the treatment of Plaque psoriasis.

### Rimegepant: Biohaven Pharmaceuticals

Biohaven's Nurtec ODT (rimegepant) Received FDA Approval in February 2020. Nurtec ODT is the first and only CGRP receptor antagonist available in an orally disintegrating tablet (ODT) for the acute treatment of migraine, and the only oral CGRP receptor antagonist with product label claims including return to normal functioning and sustained durability of efficacy up to 48 hours after a single dose. It is currently in phase 2 of development stage for the treatment of Plaque psoriasis.

### JTE-451: Akros Pharma

JTE 451 is a small molecule antagonists for the orphan nuclear receptor ROR $\gamma$  (nuclear receptor subfamily 1 group F member 3 antagonist), being developed by Japan Tobacco, as an oral formulation for the treatment of autoimmune and allergic disorders.

### GR-MD-02: Galectin Therapeutics

GR-MD-02 (belapectin) is an inhibitor of galectin. It binds to galectin-3 proteins and disrupts its function. Belapectin is the first drug in a large, randomized clinical trial to

demonstrate a clinically meaningful improvement in portal hypertension or liver biopsy in patients with NASH cirrhosis without varices.

#### ESR-114: Escalier Biosciences

ESR-114 topical gel is a selective, potent inhibitor of ROR $\gamma$ t designed to have its pharmacological activity targeted to the skin with minimal systemic absorption. ESR-114 topical gel is currently being evaluated to determine if it may reduce or treat the clinical manifestations of psoriasis. It is currently in phase 1/2 of development stage for the treatment of Plaque psoriasis.

Further product details are provided in the report

#### Psoriasis: Therapeutic Assessment

This segment of the report provides insights about the different Psoriasis drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in Psoriasis

There are approx. 100+ key companies which are developing the therapies for Psoriasis. The companies which have their Psoriasis drug candidates in the most advanced stage, i.e. preregistration include, UCB.

#### Phases

DelveInsight's report covers around 100+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intramuscular

Transdermal

Topical.

Intravenous

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

### Psoriasis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Psoriasis therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Psoriasis drugs.

### Psoriasis Report Insights

- Psoriasis Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

### Psoriasis Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

### Key Questions

## Current Treatment Scenario and Emerging Therapies:

How many companies are developing Psoriasis drugs?

How many Psoriasis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Psoriasis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Psoriasis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Psoriasis and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Arcutis Biotherapeutics

Sinocelltech Ltd.

FYB202 GmbH & Co. KG

Celltrion

Coherus BioSciences

Janssen Pharmaceuticals

Can-Fite Biopharma

Arcutis Biotherapeutics, Inc.

Amgen

GlaxoSmithKline

Galectin Therapeutics Inc.

Evelo Biosciences, Inc.

Galderma R&D

BioMimetix JV, LLC

Boehringer Ingelheim

Aurigene Discovery Technologies Limited

AnaptysBio, Inc.

AmDerma

Akeso

Affibody

Menlo Therapeutics Inc.

Aristea Therapeutics

UNION Therapeutics

MetrioPharm AG

Provectus Pharmaceuticals

Sienna Biopharmaceuticals

Santalis Pharmaceuticals



Atridia Pty Ltd.

Dr. Reddy's Laboratories Limited

Galderma R&D

AB Science

Lycera Corp.

LEO Pharma

Kadmon Corporation, LLC

Akros Pharma Inc.

Athenex

DelArrivo

Theramab LLC

AbbVie

AstraZeneca

Immunic

Bio-Thera Solutions

CSL Behring

Palbiofarma

SFA Therapeutics

NeuClone

Galapagos NV

Boston Pharmaceuticals

Cellenkos

Sareum

Temisis Therapeutics

Dice Molecules

Aclaris Pharma

Midatech Pharma

Xbrane Biopharma

## Key Products

Roflumilast

SCT630

FYB202

CT-P43

CHS-1420

Guselkumab

Piclidenoson

ARQ-154

ABP 654

GSK2982772

GR-MD-02

EDP1815

CD10367

BMX-010

BI 730357

AUR 101

AM001

AK101

ABY-035

Serlopitant

RIST4721

UNI-50001

MP1032

UHE-105

Topical Rose Bengal

SNA-120

SAN021

SHR-1314

PPC-06

PF-07038124

NP000888

Masitinib

LYC-30937-EC

LEO 22811

KD025

JTE-451

Tirbanibulin

DLX105-DMP

TAB08

ABBV-157

AZD0284

AK111

IMU 935

BAT2206

CSL324

PBF-1650

SFA 002

NeuLara

GLPG3970

BOS-475

CK 0801

SDC 1801

TEM1657

MTX114

ATI-2138

Xcimbane

## Contents

- Introduction
- Executive Summary
- Psoriasis: Overview
  - Causes
  - Mechanism of Action
  - Signs and Symptoms
  - Diagnosis
  - Disease Management
- Pipeline Therapeutics
  - Comparative Analysis
- Therapeutic Assessment
  - Assessment by Product Type
  - Assessment by Stage and Product Type
  - Assessment by Route of Administration
  - Assessment by Stage and Route of Administration
  - Assessment by Molecule Type
  - Assessment by Stage and Molecule Type
- Psoriasis – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
  - Psoriasis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Psoriasis Collaboration Deals
  - Company-Company Collaborations (Licensing / Partnering) Analysis
  - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Preregistration)
  - Comparative Analysis
- Bimekizumab: UCB
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
  - Comparative Analysis
- MP1032: MetrioPharm
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....

**Early Stage Products (Phase I/II)**

Comparative Analysis

**ESR-114: Escalier Biosciences**

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

**Preclinical and Discovery Stage Products**

Comparative Analysis

**ATI-2138: Aclaris Therapeutics**

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

**Inactive Products**

Comparative Analysis

**Psoriasis Key Companies****Psoriasis Key Products****Psoriasis- Unmet Needs****Psoriasis- Market Drivers and Barriers****Psoriasis- Future Perspectives and Conclusion****Psoriasis Analyst Views****Psoriasis Key Companies****Appendix**

## List Of Tables

### LIST OF TABLES

- Table 1 Total Products for Psoriasis
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products



## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Psoriasis
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Psoriasis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/PAC646203B9AEN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PAC646203B9AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970